Bluejay Diagnostics Announces 1-For-8 Reverse Stock Split, Will Open For Trading On The Nasdaq Capital Market On A Post-Split Basis On June 20, 2024

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-8 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on June 20, 2024, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on June 20, 2024 under the Company's existing trading symbol, "BJDX." At such time, the Company's common stock will also commence trading with a new CUSIP number, 095633400.